[Webinar] Cannabis Rescheduling: Implications and Next Steps

May 3, 2024

It was reported on April 30, 2024 that the U.S. Drug Enforcement Administration will reclassify cannabis from Schedule I to Schedule III, per the August recommendation from the U.S. Department of Health and Human Services. Rescheduling is neither the perfect nor final solution, but it represents a historic and critically important shift in U.S. drug policy with dramatic and long-term societal impacts for medicine, patients, and the cannabis industry.

Watch this special briefing featuring Vicente LLP leaders who have been deeply immersed in the federal scheduling issue, along with Mitzi Keating, a CPA and partner at Citrin Cooperman.  

Key topics will include:

  • DEA’s decision and the timeline, next steps, and potential hurdles in the rescheduling process
  • Implications for the state-legal cannabis industry, including federal enforcement efforts, the 280E tax issue, banking access, intellectual property opportunities and considerations, and other practical business considerations
  • The road ahead for further cannabis-related policy reform, interstate commerce, and social equity


The content and links provided on this page are for informational purposes only and not for the purpose of providing legal or tax advice. Viewing this page does not establish an attorney-client relationship. You should consult with a qualified legal professional for advice regarding any particular issue or problem. The contents of this page may be considered attorney advertising under certain rules of professional conduct.